Endo Q1 revenue down 6% to $392.8M, net loss $128.6M; reaffirms FY guidance; President of Global Commercial Ops resigns

Endo LP

2025-Q1 EPS reported -$1.69 revenue$392,833,000

Total revenues $392.8M (-6% YoY), net loss $128.6M (improved from $154.2M loss in Q1 2024).
XIAFLEX revenues grew 7% YoY; Sterile Injectables down 27% to $71.3M.
Reaffirmed 2025 revenue guidance: $1,775-$1,860M; adjusted EBITDA: $620-$650M.
Combination with Mallinckrodt expected to close in second half of 2025.
Patrick A. Barry (President Global Commercial Ops) resigns effective May 30, 2025; no severance.

item 2.02 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Patrick A. Barry

Executive Vice President, President Global Commercial Operations

Endo LP

Effective: 2025-05-30
Filed: May 7, 2025, 7:59 PM ET

On May 6, 2025, Patrick A. Barry, Executive Vice President, President Global Commercial Operations, notified the Company of his intent to resign, effective as of May 30, 2025, in order to accept a position with another company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Patrick A. Barry resigned as Executive Vice President, President Global Commercial Operations at Endo LP.

Action: resigned
Role: Executive Vice President, President Global Commercial Operations

Exact text from the filing

On May 6, 2025, Patrick A. Barry, Executive Vice President, President Global Commercial Operations, notified the Company of his intent to resign, effective as of May 30, 2025, in order to accept a position with another company.

View on SEC.gov

Source: SEC EDGAR

accession 0002008861-25-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.